/EXEL
Exelixis, Inc.
EXEL • NASDAQEXEL • NASDAQ • Healthcare
$41.30+0.32%+0.13
$41.30+0.32%(+0.13)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
82Bullish
Risk
100Low Risk
Momentum
41Neutral
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
96.4%▼0.1pp
Revenue after COGS
Operating
37.6%▲9.7pp
After operating expenses
Net
33.7%▲9.7pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
15.1
Price vs earnings
EV/EBITDA
12.5
Enterprise value
FCF Yield
7.1%
Cash generation
Earnings Yield
6.6%
Inverse of P/E
Capital Efficiency
31
GoAI Quality ScoreExcellent
ROEReturn on Equity
36.2%Strong
ROAReturn on Assets
27.5%Strong
ROICReturn on Invested Capital
29.7%Strong
Financial Health
Current RatioHealthy
3.56
Short-term solvency (>1.5)
Net Debt / EBITDANet Cash
-0.34x
Debt repayment capacity (<3x)
Income QualityStrong
1.13
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B |
| Gross Profit | $2.24B | $2.09B | $1.76B | $1.55B | $1.38B |
| Gross Margin | 96.4% | 96.5% | 96.0% | 96.4% | 96.3% |
| Operating Income | $872.19M | $604.62M | $170.88M | $201.48M | $286.67M |
| Net Income | $782.57M | $521.27M | $207.76M | $182.28M | $231.06M |
| Net Margin | 33.7% | 24.0% | 11.4% | 11.3% | 16.1% |
| EPS | $2.88 | $1.80 | $0.65 | $0.57 | $0.73 |
Average Price Target
$44.40▲ 7.5% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Exelixis, Inc., the average price target is $44.40, with a high forecast of $54.00 and a low forecast of $30.00. The average price target represents a 7.5% increase from the current price of $41.30.
Highest
$54.00
Average
$44.40
Lowest
$30.00
Rating Distribution
Strong Buy
0
0%
Buy
16
50%
Hold
16
50%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
RBC Capital● Maintain
Sector Perform
2026-03-02HC Wainwright & Co.● Maintain
Buy
2026-02-12Stifel● Maintain
Hold
2026-02-11RBC Capital● Maintain
Sector Perform
2026-02-11Wells Fargo● Maintain
Equal Weight
2026-02-11Barclays● Maintain
Equal Weight
2026-02-04HC Wainwright & Co.● Maintain
Buy
2026-02-03Morgan Stanley● Maintain
Equal Weight
2026-02-02HC Wainwright & Co.● Maintain
Buy
2026-01-27HC Wainwright & Co.● Maintain
Buy
2026-01-08Earnings History & Surprises
BEAT RATE
78%
Last 18 quarters
AVG SURPRISE
+45.0%
EPS vs Estimate
BEATS / MISSES
14/3
1 met exactly
LATEST EPS
$0.94
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+22.1%
$0.94 vs $0.77
Q4 '25
+13.9%
$0.78 vs $0.69
Q3 '25
+15.4%
$0.75 vs $0.65
Q2 '25
+73.1%
$0.62 vs $0.36
Q1 '25
+7.8%
$0.55 vs $0.51
Q4 '24
+14.3%
$0.40 vs $0.35
Q3 '24
+156.7%
$0.77 vs $0.30
Q2 '24
-39.3%
$0.17 vs $0.28
Q1 '24
+28.6%
$0.27 vs $0.21
Q4 '23
$0.10 vs $0.10
Q3 '23
+56.3%
$0.25 vs $0.16
Q2 '23
-20.0%
$0.12 vs $0.15
No investor questions available.
Latest News
No news available